Form 4: Regeneron EVP Marion McCourt Executes Stock Option and Sells Shares Under 10b5-1 Plan

Marion McCourt, EVP Commercial at Regeneron Pharmaceuticals, exercised stock options and sold shares of common stock on August 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On August 1, 2024, Marion McCourt, the EVP Commercial at Regeneron Pharmaceuticals, exercised a non-qualified stock option to acquire 1,137 shares of Regeneron common stock at a price of $372.46 per share.
• Simultaneously, McCourt sold 1,137 shares of Regeneron common stock at a price of $1,060.86 per share.
• These transactions were executed under a pre-arranged trading plan intended to comply with Rule 10b5-1(c), which was adopted on February 13, 2024.
• Following these transactions, McCourt directly owns 12,931 shares of Regeneron common stock and indirectly owns 174 shares through a 401(k) plan.
• McCourt also continues to hold options for an unspecified number of shares that vest in four equal annual installments, commencing one year after the grant date.

Sentiment

Score: 5

Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, indicating a neutral sentiment.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often governed by pre-arranged trading plans like the 10b5-1 plan to avoid accusations of insider trading. These transactions can provide insights into executive sentiment, although they are often driven by personal financial planning needs.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are standard practice among publicly traded pharmaceutical companies like Regeneron.
• Companies such as Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their executive compensation strategy.
• The use of 10b5-1 trading plans is a common method for executives to manage their stock holdings while complying with insider trading regulations, similar to practices seen at Pfizer and Merck.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares involved.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates